The U.S. Food and Drug Administration approved AbbVie's Juvmo (tavapadon) on Friday, Sept. 25, for adults with Parkinson's disease. The once-daily pill represents the first FDA-approved Parkinson's treatment to selectively activate D1/D5 dopamine receptors—a mechanism designed to restore motor control lost as the disease destroys dopamine-producing cells.
Juvmo is the flagship asset from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, completed in 2024. For investors, the approval matters immediately: it validates the Cerevel price tag and proves AbbVie can execute on its neuroscience strategy as Humira faces irreversible patent cliff erosion.
AbbVie projects Juvmo will generate $8 million in revenue in 2026 and $70 million in 2027, ramping to $1.4 billion annually by 2040. Those figures assume significant market penetration in a Parkinson's patient population exceeding 10 million globally. The drug will be available to U.S. patients in October 2026.
Context: AbbVie's neuroscience portfolio—Vraylar, Ubrelvy, and Qulipta—generated approximately $5.9 billion in combined 2025 sales. Juvmo enters a portfolio undergoing aggressive expansion. Humira, which once generated over $20 billion annually, has lost U.S. patent exclusivity; Juvmo and similar launches are central to AbbVie's survival strategy of replacing blockbuster dependence with diversified franchises across neuroscience, immunology, and oncology.
Watchers should monitor real-world uptake data beginning in late 2026. Market share gains in Parkinson's depend on both efficacy durability and physician adoption—competitive pressure from other dopamine-targeting therapies and established treatments remains high. The $1.4 billion 2040 projection is achievable only if Juvmo maintains clinical credibility and AbbVie's sales force executes.
